| Drug Candidate | Clinical Focus | Discovery | IND enabling | Phase 1 | Phase 2 | Phase 3 |
|---|---|---|---|---|---|---|
| Cizutamig (BCMA/CD3) |
Autoantibody driven autoimmune diseases1 | |||||
| CND261 (CD20/CD3) |
Autoimmune diseases2 | |||||
| CND319 (CD19/CD20/CD3) |
Autoimmune diseases | |||||
| CND460 (BCMA/CD19/CD3) |
Autoimmune diseases | |||||
| Discovery | IND enabling | Phase 1 | Phase 2 | Phase 3 |
| Cizutamig (BCMA/CD3) | ||||
| Autoantibody driven autoimmune diseases1 | ||||
| CND261 (CD20/CD3) | ||||
| Autoimmune diseases2 | ||||
| CND319 (CD19/CD20/CD3) | ||||
| Autoimmune diseases | ||||
| CND460 (BCMA/CD19/CD3) | ||||
| Autoimmune diseases | ||||
1Phase 1 multiple myeloma (MM) completed (40 patients)
2Phase 1 Non-Hodgkin’s lymphoma (NHL) completed (93 patients)
CIZUTAMIG (BCMAxCD3) Antibody
Cizutamig is a bispecific antibody that can bind to B-cell maturation antigen (BCMA) on B-cells and CD3 on T-cells, enabling T-cell–mediated cytotoxicity against BCMA-expressing B-cells. Purposely designed to maintain cytotoxicity while limiting cytokine release, cizutamig has been clinically evaluated in patients with multiple myeloma and autoimmune diseases. Cizutamig is currently in multiple clinical studies across various autoimmune diseases.
CND261 (CD20xCD3) Antibody
CND261 is a CD20xCD3 bispecific antibody designed to target a broad range of B-cell subtypes, from pro B-cells to plasmablasts/plasma cells. While several CD20-based antibodies have already demonstrated clinical benefit in various autoimmune conditions, CND261’s unique T-cell engager technology has the potential to significantly enhance efficacy. Having successfully completed a Phase 1 dose escalation study in oncology patients, Candid is now developing CND261 to address unmet needs in autoimmune diseases.
CND319 (CD19xCD20xCD3) Antibody
CND319 is a CD19xCD20xCD3 trispecific antibody designed to target the CD19 and CD20 antigens on a broad range of B-cell subtypes. CND319 is currently undergoing IND enabling studies.
CND460 (BCMAxCD19xCD3) Antibody
CND460 is a BCMAxCD19xCD3 trispecific antibody designed to target the BCMA and CD19 antigens on a broad range of B-cell subtypes. CND460 is currently undergoing IND enabling studies.